RT Journal Article
T1 HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018.
A1 Pérez-Latorre, Leire
A1 Berenguer, Juan
A1 Micán, Rafael
A1 Montero, Marta
A1 Cifuentes, Carmen
A1 Puig, Teresa
A1 Sanz, José
A1 Ferrero, Oscar L
A1 De La Fuente, Belén
A1 Rodríguez, Carmen
A1 Reus, Sergio
A1 Hernández-Quero, José
A1 Gaspar, Gabriel
A1 Pérez-Martínez, Laura
A1 García, Coral
A1 Force, Luis
A1 Veloso, Sergio
A1 De Miguel, Marta
A1 Jarrín, Inmaculada
A1 González-García, Juan
A1 GeSIDA 8514 Study Group, 
K1 HBV therapy
K1 HIV/HBV coinfection
K1 hepatitis delta virus
AB BackgroundRecent and reliable estimates on the prevalence of coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) in Europe are lacking.AimLeveraged on a study designed to assess HIV/HCV coinfection prevalence, we assessed the prevalence of HIV/HBV coinfection in Spain in 2018 and compared the results with five similar studies performed since 2002.MethodsThis cross-sectional prevalence study was carried out in 43 centres, and patients were selected using simple random sampling. The reference population comprised 40,322 patients and the sample size were 1,690 patients.ResultsThe prevalence of HIV/HBV coinfection in Spain at the end of 2018 was 3.2%. The prevalence in 2002, 2009, 2015, 2016 and 2017 was 4.9%, 3.4%, 3%, 3.9% and 3%, respectively. Among the HIV/HBV-coinfected patients identified in 2018, 16.7% had cirrhosis according to transient elastography and 26.3% tested positive for antibodies against hepatitis D virus. All HIV/HBV-coinfected patients were receiving drugs with activity against HBV, and 97% of those tested for HBV DNA had an HBV DNA load 
YR 2021
FD 2021
LK http://hdl.handle.net/10668/18041
UL http://hdl.handle.net/10668/18041
LA en
DS RISalud
RD Apr 10, 2025